Cargando…

High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection

SARS-CoV-2 nucleocapsid protein (NP) is the main target for COVID-19-diagnostic PCR and antigen rapid diagnostic tests (Ag-RDTs). Ag-RDTs are more convenient than PCR tests for point-of-care testing or self-testing to identify the SARS-CoV-2 antigen. The sensitivity and specificity of this method de...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujisawa, Mizuki, Adachi, Yu, Onodera, Taishi, Shiwa-Sudo, Nozomi, Iwata-Yoshikawa, Naoko, Nagata, Noriyo, Suzuki, Tadaki, Takeoka, Shinji, Takahashi, Yoshimasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279465/
https://www.ncbi.nlm.nih.gov/pubmed/37379800
http://dx.doi.org/10.1016/j.bbrc.2023.06.067
_version_ 1785060598608822272
author Fujisawa, Mizuki
Adachi, Yu
Onodera, Taishi
Shiwa-Sudo, Nozomi
Iwata-Yoshikawa, Naoko
Nagata, Noriyo
Suzuki, Tadaki
Takeoka, Shinji
Takahashi, Yoshimasa
author_facet Fujisawa, Mizuki
Adachi, Yu
Onodera, Taishi
Shiwa-Sudo, Nozomi
Iwata-Yoshikawa, Naoko
Nagata, Noriyo
Suzuki, Tadaki
Takeoka, Shinji
Takahashi, Yoshimasa
author_sort Fujisawa, Mizuki
collection PubMed
description SARS-CoV-2 nucleocapsid protein (NP) is the main target for COVID-19-diagnostic PCR and antigen rapid diagnostic tests (Ag-RDTs). Ag-RDTs are more convenient than PCR tests for point-of-care testing or self-testing to identify the SARS-CoV-2 antigen. The sensitivity and specificity of this method depends mainly on the affinity and specificity of NP-binding antibodies; therefore, antigen-antibody binding is key elements for the Ag-RDTs. Here, we applied the high-throughput antibody isolation platform that has been utilized to isolate therapeutic antibodies against rare epitopes. Two NP antibodies were identified to recognize non-overlapping epitopes with high affinity. One antibody specifically binds to SARS-CoV-2 NP, and the other rapidly and tightly binds to SARS-CoV-2 NP with cross-reactivity to SARS-CoV NP. Furthermore, these antibodies were compatible with a sandwich enzyme-linked immunosorbent assay that exhibited enhanced sensitivity for NP detection compared to the previously isolated NP antibodies. Thus, the NP antibody pair is applicable to more sensitive and specific Ag-RDTs, highlighting the utility of a high-throughput antibody isolation platform for diagnostics development.
format Online
Article
Text
id pubmed-10279465
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-102794652023-06-21 High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection Fujisawa, Mizuki Adachi, Yu Onodera, Taishi Shiwa-Sudo, Nozomi Iwata-Yoshikawa, Naoko Nagata, Noriyo Suzuki, Tadaki Takeoka, Shinji Takahashi, Yoshimasa Biochem Biophys Res Commun Article SARS-CoV-2 nucleocapsid protein (NP) is the main target for COVID-19-diagnostic PCR and antigen rapid diagnostic tests (Ag-RDTs). Ag-RDTs are more convenient than PCR tests for point-of-care testing or self-testing to identify the SARS-CoV-2 antigen. The sensitivity and specificity of this method depends mainly on the affinity and specificity of NP-binding antibodies; therefore, antigen-antibody binding is key elements for the Ag-RDTs. Here, we applied the high-throughput antibody isolation platform that has been utilized to isolate therapeutic antibodies against rare epitopes. Two NP antibodies were identified to recognize non-overlapping epitopes with high affinity. One antibody specifically binds to SARS-CoV-2 NP, and the other rapidly and tightly binds to SARS-CoV-2 NP with cross-reactivity to SARS-CoV NP. Furthermore, these antibodies were compatible with a sandwich enzyme-linked immunosorbent assay that exhibited enhanced sensitivity for NP detection compared to the previously isolated NP antibodies. Thus, the NP antibody pair is applicable to more sensitive and specific Ag-RDTs, highlighting the utility of a high-throughput antibody isolation platform for diagnostics development. Elsevier Inc. 2023-09-17 2023-06-19 /pmc/articles/PMC10279465/ /pubmed/37379800 http://dx.doi.org/10.1016/j.bbrc.2023.06.067 Text en © 2023 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Fujisawa, Mizuki
Adachi, Yu
Onodera, Taishi
Shiwa-Sudo, Nozomi
Iwata-Yoshikawa, Naoko
Nagata, Noriyo
Suzuki, Tadaki
Takeoka, Shinji
Takahashi, Yoshimasa
High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection
title High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection
title_full High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection
title_fullStr High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection
title_full_unstemmed High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection
title_short High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection
title_sort high-throughput isolation of sars-cov-2 nucleocapsid antibodies for improved antigen detection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279465/
https://www.ncbi.nlm.nih.gov/pubmed/37379800
http://dx.doi.org/10.1016/j.bbrc.2023.06.067
work_keys_str_mv AT fujisawamizuki highthroughputisolationofsarscov2nucleocapsidantibodiesforimprovedantigendetection
AT adachiyu highthroughputisolationofsarscov2nucleocapsidantibodiesforimprovedantigendetection
AT onoderataishi highthroughputisolationofsarscov2nucleocapsidantibodiesforimprovedantigendetection
AT shiwasudonozomi highthroughputisolationofsarscov2nucleocapsidantibodiesforimprovedantigendetection
AT iwatayoshikawanaoko highthroughputisolationofsarscov2nucleocapsidantibodiesforimprovedantigendetection
AT nagatanoriyo highthroughputisolationofsarscov2nucleocapsidantibodiesforimprovedantigendetection
AT suzukitadaki highthroughputisolationofsarscov2nucleocapsidantibodiesforimprovedantigendetection
AT takeokashinji highthroughputisolationofsarscov2nucleocapsidantibodiesforimprovedantigendetection
AT takahashiyoshimasa highthroughputisolationofsarscov2nucleocapsidantibodiesforimprovedantigendetection